2011 Publications

NoTitleAuthorsYear
1A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trialJacob ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs JD, Koblin B, Griffith S, Wald A, Celum C2011
2Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in ZambiaMwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, Mudenda V, Hicks ML, Vermund SH, Stringer JS, Parham GP2011
3Causes of stillbirth, neonatal death, and early childhood death in rural Zambia by verbal autopsy assessmentsTurnbull E, Lembalemba MK, Guffey MB, Bolton-Moore C, Mubiana-Mbewe M, Chintu N, Giganti MJ, Nalubamba-Phiri M, Stringer EM, Stringer JS, Chi BH2011
4CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV preventionDorton B, Mulindwa J, Li MS, Chintu NT, Chibwesha CJ, Mbewe F, Frenkel LM, Stringer JSA, Chi BH2011
5Comparative outcomes of tenofovir- and zidovudine-based antiretroviral therapy regimens in Lusaka, ZambiaChi BH, Mwango A, Giganti M, Sikazwe I, Moyo C, Schuttner L, Mulenga LB, Bolton-Moore C, Chintu NT, Sheneberger R, Stringer EM, Stringer JSA2011
6Determinants of stillbirth in Lusaka, ZambiaStringer EM, Vwalika B, Killam WP, Giganti MJ, Mbewe R, Chi BH, Chintu N, Rouse DJ, Goldenberg RL, Stringer JSA2011
7Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and SwitzerlandSchoni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L, Bucher HC, Westfall AO, Calmy A, Boulle A, Chintu N, Egger M, Chi BH2011
8HIV, hepatitis B, and hepatitis C in ZambiaKapembwa KC, Goldman JD, Lakhi S, Banda Y, Bowa K, Vermund SH, Mulenga J, Chama D, Chi BH2011
9Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the first year of antiretroviral therapy among HIV-infected Zambian and Kenyan womenDao CN, Peters PJ, Kiarie JN, Zulu I, Muiruri P, Ong’ech J, Mutsotso W, Potter D, Njobvu L, Stringer JS, Borkowf CB, Bolu O, Weidle PJ2011
10Modern contraception and dual method use among HIV-infected women in Lusaka, ZambiaChibwesha CJ, Li MS, Matoba C, Mbewe R, Chi BH, Stringer JSA, Stringer EM2011
11Nevirapine for the prevention of mother-to-child transmission of HIV: a nationwide coverage survey in Cote d’IvoireCoffie PA, Kanhon SK, Toure H, Ettiegne-Traore V, Stringer E, Stringer J, Dabis F, Ekouevi DK2011
12Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in ZambiaKoethe JR, Blevins M, Nyirenda C, Kabagambe EK, Shepherd BE, Wester CW, Chiasera JM, Mulenga LB, Mwango A, Heimburger DC2011
13Opt-out provider-initiated HIV testing and counseling in primary care outpatient clinics in ZambiaTopp SM, Chipukuma JM, Chiko MM, Wamulume CS, Bolton-Moore C, Reid SE2011
14Optimal time on HAART for prevention of mother-to-child transmission of HIVChibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, Chi BH, Stringer JSA, Stringer EM2011
15Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern AfricaKeiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Cornell M, Phiri S, Maxwell N, Maskew M, Prozesky H, Fox MP, Westfall A, Egger M2011
16Predictors of CD4 eligibility for antiretroviral therapy initiation among HIV-infected pregnant women in Lusaka, ZambiaLiu KC, Mulindwa J, Giganti MJ, Putta NB, Chintu N, Chi BH, Stringer JS, Stringer EM2011
17Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapineBoltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, McIntyre J, Currier JS, Chibowa MC, Kanyama C, Nair A, Owino-Ong'or W, Hughes M, Coffin JM, Mellors JW: OCTANE ACTG 5208 study2011
18Safety and effectiveness of BufferGel and 0.5% PRO2000 Gel for the prevention of HIV infection in womenAbdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Masse B, Hillier S, Soto-Torres L: HIV Prevention Trials Network (HPTN) 035 Study Team2011
19Timing of antiretroviral therapy for HIV-1 infection and tuberculosisHavlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I2011
20Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 health facilities across Africa, Asia, and Latin AmericaChi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, Brinkhof MWG, Mwango A, Balestre E, Carriquiry G, Sirisanthana T, Mukumbi H, Martin JN, Grimsrud A, Bacon M, R Thiebaut2011